Overview
AZN market data
Price History
AZN price chart
Valuation & Profitability
- P/E (TTM)
- 23.84 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $6.55 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.36 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 2.0% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 17.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $10,784.00 – $15,730.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $184.5B · P/B 5.91 · P/S 4.06.
Company News
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder DrugBenzinga · Aug 13, 2026, 5:07 PM
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes ShapeBenzinga · Aug 13, 2026, 3:21 PM
Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All ChildrenBenzinga · Aug 10, 2026, 7:00 PM
AstraZeneca shares are trading higher after reports suggesting that the company didn't have any merger discussions with Bristol Myers Squibb.Benzinga · Aug 5, 2026, 2:15 PM
"There Are 'No Discussions' Happening Between AstraZeneca And Bristol Myers Squibb Over Potential Deal, A Senior Source Close To Matter Says; 'Never Was A Deal To Be Done' Between AstraZeneca And Bristol Myers Squibb" - Reuters ExclusiveBenzinga · Aug 5, 2026, 12:06 PM
SOPHiA GENETICS Announces Global Collaboration To Develop, Validate, And Deploy Two Companion Diagnostics Supporting Precision Oncology Therapies With AstraZenecaBenzinga · Aug 4, 2026, 10:19 AM
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in FocusBenzinga · Aug 3, 2026, 5:13 PM
Yen Intervention And Falling Oil Help Stocks, But Selling In Korea Throws A Monkey WrenchBenzinga · Aug 3, 2026, 4:45 PM
Why Is Bristol-Myers Squibb Stock Surging Monday?Benzinga · Aug 3, 2026, 12:42 PM
Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-MergerBenzinga · Aug 3, 2026, 12:27 PM